Analysis showed that PFS was better in the pirtobrutinib group compared with the bendamustine group, with 24-month PFS rates of 93.4% and 70.7%, respectively. More work will be needed to determine the ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

When larger banks stepped out of the reverse mortgage market in the 2010s, Finance of America gobbled up much of the demand and became the second-largest reverse mortgage provider after Mutual of ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Washington, D.C.: The Executive Board of the International Monetary Fund (IMF) has formally completed its review of the Short-Term Liquidity Line (SLL) on December 15th. The Review concluded that the ...

Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...

At a median duration of follow-up of 6.6 months, treatment with pirtobrutinib reduced the risk of progression or death by 42%. The Food and Drug Administration (FDA) has approved Jaypirca ® ...

Experts say we’re in a golden age for treating chronic kidney disease, with new drugs like Ozempic yielding major results. Will dialysis and organ transplants become a thing of the past? A healthy ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

All websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings ...